

Wednesday April 11, 2018

12:00 - 1:00 PM Registration & Poster set up

1:00 - 1:30 PM Opening

Session 1 - 1:30-3:00 PM - Co-morbidities

Session chairs: Johannes Ring, Christian Vestergaard

1:30 – 2:00 Comorbidities of atopic dermatitis: association or systemic disease? Invited speaker: Jonathan Silverberg, USA

2:00 - 2:15

O01 HSV1- and influenza-specific T-cells are of a Th2/Tc2 type in patients with a history of eczema herpeticum, *L.M. Roesner, Germany*

2:15 - 2:30

O02 Atopic dermatitis and subsequent suicide: a matched case-control study, *A.M. Drucker, Canada* 2:30 – 2:45

O03 Eczema and mental health among pregnant women in the Japan environment and children's study (JECS), *K. Yamamoto-Hanada, Japan* 2:45 – 3:00

O04 Association with depression, anxiety and suicidal ideation in children and adults with atopic dermatitis: A systematic review and meta-analysis, *A. Halling-Overgaard, Denmark*

3:00 - 3:30 PM Break

Session 2 – 3:30-5:00 PM – Patients' perspectives/ Education/ eHealth Session chairs: Roberto Takaoka, Sebastien Barbarot

3:30 – 4:00 Atopic dermatitis – the patient perspective Invited speaker: Matthew Ridd, United Kingdom

4:00 - 4:15

O05 Empowering physicians and educating patients in the 21st century: A novel, low-cost, multimodal intervention for atopic dermatitis care, *A. Han, USA*

4:15 - 4:30

O06 Improvement of atopic dermatitis, coping and quality of life in adult patients participating in a structured educational training, *A. Heratizadeh, Germany*

4.30 - 4.15

O07 Precision medicine in atopic dermatitis: generation of quantity-of-use estimates for topical therapies, *A. Kusari, USA*

4:45 - 5:00

O08 Development of at-home measurement device for skin barrier functions integrated with IOT technology for ad education, *H.J. Kim, South Korea*

7:00 PM Conference Dinner (ticketed) – Museum Speelklok Georg Rajka medal ceremony



Thursday, April 12, 2018

Session 3a - 9:00-10:30 AM - Mechanisms of disease: genetics & -omics

Session chairs: Thomas Werfel, Kyu Han Kim

9:00 - 9:30

Invited speaker: John Common, Singapore

9:30 - 9:45

O09 The role of CXCR4-expressing skin-resident NKT cells in atopic dermatitis, *C.O. Park*, *South Korea*

9:45 - 10:00

O10 What is the evidence for interactions between filaggrin null mutations and environmental exposures in the aetiology of eczema? *H.C.J. Blakeway, United Kingdom* 10:00 – 10:15

Q11 Role of brain-derived natriuretic peptide in atopic dermatitis, *M.S. Steinhoff, Qatar* 10:15 – 10:30

O12 Salivary chromogranin a levels correlate with disease severity but not reflect anxiety by questionnaire survey with adult atopic dermatitis patients, *S.K. Kaneko, Japan*

10:30 - 11:00 AM Break

Session 3b – 11:00 AM-12:30 PM – Mechanisms of disease: from phenotypes to endotypes Session chairs: Emma Guttman, Norito Katoh

11:00 - 11:30

Invited speaker: Thomas Bieber, Germany

11:30 - 11:45

O13 Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis, *J.L. Thijs, The Netherlands*

11:45 - 12:00

O14 Longitudinal latent class analysis identifies distinct subgroups of paediatric atopic eczema, S.J. Brown, United Kingdom

12:00 - 12:15

O15 Stratum corneum biomarkers of skin barrier and immune response in atopic dermatitis children with different skin types; an explorative study, *M.A. Middelkamp-Hup, The Netherlands* 12:15 – 12:30

O16 A model that integrates skin and blood atopic dermatitis biomarkers and clinical disease severity to advance personalized medicine, *A.B. Pavel, USA*

12:30 - 1:30 PM Lunch and poster viewing



Session 4a – 1:30-3:00 PM – New targets, systemic treatments and new treatments I Session chairs: Andreas Wollenberg, Kenji Kabashima

 $1:30-2:00\,$ The Gloves are Off – AD Therapeutics are Duking it Out

Invited speaker: Lisa Beck, USA

2:00 - 2:15

O17 Comparison of the efficacy of dupilumab versus cyclosporine using EASI thresholds in adult patients with moderate to severe atopic dermatitis, *L.F.M. Ariëns*, *The Netherlands* 2:15 – 2:30

O18 From old king coal to novel treatments for atopic dermatitis: the aryl hydrocarbon receptor as a therapeutic target, *E.H. Van den Bogaard, The Netherlands*

2:30 - 2:45

O19 Effects of upadacitinib on atopic dermatitis signs, symptoms and patient-reported outcomes from a phase 2b randomized, placebo-controlled trial, *M.S. De Bruin-Weller, The Netherlands* 2:45 – 3:00

O20 MOR106, an anti-IL-17C MAb and a potential new approach for treatment of moderate to severe atopic dermatitis: Phase 1 study, *D. Thaci, Germany*

3:00 - 3:30 PM Break

Session 4b – 3:30-5:00 PM – New targets, systemic treatments and new treatments II Session chairs: Andreas Wollenberg, Kenji Kabashima

3:30 - 3:45

O21 ZPL389, novel oral histamine H4 receptor antagonist for treatment of moderate-to-severe atopic dermatitis: results of a randomized, double-blind, placebo-controlled, proof-of-concept study, *T. Werfel, Germany*

3:45 - 4:00

O22 Novel AHR ligands for the treatment of atopic dermatitis, *G. Rikken, The Netherlands* 4:00 – 4:15

O23 Predictive factors for successful long-term control of "refractory" adult atopic dermatitis by biomarker-guided tight control strategy, *Y. Kataoka, Japan*

4:15 - 4:30

O24 Short-term VTP-38543 LXR agonist topical application improves epidermal barrier features in mild-to-moderate atopic dermatitis, *N.A. Guttman-Yassky, USA*

4:30 - 5:00 Short piano recital of semi-classical songs composed by Hywel Williams

5:00 - 6:00 PM Poster viewing & drinks

6:00 - 7:00

Guest speaker - Stem cells and organoids in tomorrow's clinical practice H. Clevers, The Netherlands



Friday, April 13, 2018

Session 5 – 9:00-10:30 AM – Outcome measures Session chairs: Eric Simpson, Christian Apfelbacher

9:00 – 9:30 Demystifying Outcome Measures Invited speaker: Hywel Williams, United Kingdom

9:30 - 9:45

O25 EASI p-EASI: utilising a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients, *D.J. Hijnen, The Netherlands* 9:45 – 10:00

O26 Interpreting change in patient-oriented eczema measure scores: calculating the smallest detectable change and the minimally important change, *L.M. Howells, United Kingdom* 10:00 – 10:15

O27 What is long-term control of atopic eczema? International qualitative studies and results of the home V consensus meeting, *J.R. Chalmers, United Kingdom* 10:15 – 10:30

O28 Predicting short- and long-term outcomes of a systemic therapy for atopic dermatitis using machine learning methods, *G. Hurault, United Kingdom*

10:30 - 11:00 AM Break

Session 6 – 11:00 AM-12:30 PM – Gaps in evidence Session chairs: Thomas Bieber, Hywel Williams

11:00 - 11:30

Mind the Gap: Prioritizing the Many Unmet Needs for Research in Atopic Dermatitis Invited speaker: Amy Paller, USA

11:30 - 11:45

O29 Early introduction of proactive therapy for infantile atopic dermatitis prevents onset of food allergy, Y.O. *Ohya, Japan*

11:45 - 12:00

O30 Treatment of atopic dermatitis (treat) registry taskforce: an international exercise to harmonise data collection for national atopic eczema registries, *L.A.A. Gerbens, The Netherlands* 12:00 – 12:15

O31 Evaluation of antimicrobial textiles for atopic dermatitis, *J. Srour, Germany* 12:15 – 12:30

O32 Salivary cortisol testing for Hypothalamic-Pituitary-Adrenal axis (HPA) suppression in children with atopic dermatitis treated with topical corticosteroids, *M. Kim, Australia*

12:30 PM Prizes for best posters and oral Closing remarks and Farewell